Growth in sequencing array and consumables sales enables this genomic-sequencing leader to post solid Q2 results.
Volume growth from the cancer-test maker was outstanding, and while there's work to go on reimbursement, revenue increased 19% year over year.
A pre-announcement of disappointing first-quarter financials weighed down shares in this gene-sequencing giant.
Sluggish European sales causes the genomic sequencing company to stumble in Q1.
Investments by the lab-test maker hurt first-quarter earnings but should pay off later in 2016.
The cancer-test maker is on the road to profitability.
Illumina shares are dropping, and Pacific Biosciences' are climbing, but investors may not want to count Illumina out.
Illumina Corp's gene sequencing machines are reshaping how doctors will treat patients in the decades to come.
Lackluster sales growth is causing shares to drop, but long-minded investors may want to consider buying.
Lower-than-hoped first quarter performance is weighing down shares.